Kymera Therapeutics (NASDAQ:KYMR) Provides Business Update and Preliminary Cash Balance for 2024
Kymera Therapeutics, Inc., a leader in targeted protein degradation, recently released its preliminary cash balance for December 31, 2024, along with a business update outlining key objectives for 2025. As reported in their Form 8-K filing dated January 14, 2025, the company estimates having approximately $850 million in cash, cash equivalents, and marketable securities as […]
More Stories
Banyan Gold (CVE:BYN) Shares Down 2.6% – Here’s Why
Shares of Banyan Gold Corp. (CVE:BYN – Get Free Report) fell 2.6% during trading on Thursday . The stock traded...
Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG) Position Increased by Rovin Capital UT ADV
Rovin Capital UT ADV boosted its holdings in Schwab U.S. Large-Cap Growth ETF (NYSEARCA:SCHG – Free Report) by 445.6% in...
Lockheed Martin Co. (NYSE:LMT) Holdings Decreased by Financial Enhancement Group LLC
Financial Enhancement Group LLC reduced its holdings in Lockheed Martin Co. (NYSE:LMT – Free Report) by 95.8% in the 4th...
Insider Selling: Volex plc (LON:VLX) Insider Sells 6,035 Shares of Stock
Volex plc (LON:VLX – Get Free Report) insider Jon Boaden sold 6,035 shares of the company’s stock in a transaction...
AT&T (NYSE:T) Stock Rating Upgraded by Argus
AT&T (NYSE:T – Get Free Report) was upgraded by equities research analysts at Argus from a “hold” rating to a...
Kathmere Capital Management LLC Boosts Stock Position in U.S. Bancorp (NYSE:USB)
Kathmere Capital Management LLC raised its holdings in U.S. Bancorp (NYSE:USB – Free Report) by 7.1% during the fourth quarter,...